Business, energy, technology, markets and global industry news from Business News Today

Ltd.

PharmaDeviceNews Ltd.
Pharma & Biotech

Qihan Biotech gains FDA momentum for QT-019B as allogeneic CAR-T ambitions grow

Find out how Qihan Biotech’s QT-019B FDA designations could reshape autoimmune CAR-T development and what risks remain.

Read More
Representative image of neuropsychiatric drug research, as Otsuka Pharmaceutical’s Transcend Therapeutics acquisition puts TSND-201 and rapid-acting PTSD treatment innovation in focus.
Pharma & Biotech

Why Otsuka’s $1.2bn Transcend Therapeutics buyout could reshape PTSD drug development

Find out how Otsuka’s Transcend Therapeutics acquisition could reshape rapid-acting PTSD treatment development.

Read More
Representative image of oncology researchers reviewing lung cancer imaging and genomic data, reflecting Kelun-Biotech’s lunbotinib fumarate Phase II results in RET fusion-positive non-small cell lung cancer.
Pharma & Biotech

Kelun-Biotech’s ASCO 2026 data strengthens China’s next wave of targeted cancer drugs

Kelun-Biotech’s RET lung cancer data looks strong, but CNS durability and global competition will decide its real impact.

Read More
Representative image of a lung cancer treatment setting, as OptiTROP-Lung05 data put sacituzumab tirumotecan at the centre of the first-line NSCLC immunotherapy debate.
Pharma & Biotech

Can TROP2 ADCs reshape first-line NSCLC after Kelun-Biotech’s OptiTROP-Lung05 win?

A TROP2 ADC just pushed past pembrolizumab alone in first-line lung cancer. See why OptiTROP-Lung05 matters now.

Read More
Representative image of MRI brain scan analysis as Ono Pharmaceutical’s ONO-2808 trial data highlights new research momentum in multiple system atrophy treatment.
Pharma & Biotech

Why Ono’s Phase 2 MSA data may matter beyond one World Parkinson Congress poster

Ono’s ONO-2808 data hints at disease modification in MSA. See why Phase 3 may decide whether the signal becomes a breakthrough.

Read More
Representative image of Alzheimer’s disease treatment and market analysis, highlighting how Eisai’s Leqembi sales simulation could shape BioArctic’s royalty outlook, investor sentiment and the commercial future of anti-amyloid therapies.
Pharma & Biotech

Leqembi’s sales curve just got a new number. BioArctic investors may not ignore it

Leqembi’s Alzheimer’s rollout is still slow, but Eisai’s 2028 sales simulation keeps BioArctic’s royalty story alive.

Read More
Pharma & Biotech

Charles River and MEDIPOST deepen cell therapy testing push across APAC and North America

Cell therapy scale-up is not just a science problem. Charles River and MEDIPOST are targeting the GMP testing bottleneck.

Read More
Pharma & Biotech

Why GSK’s SBP Group alliance could reshape chronic hepatitis B access in Chin

China has hepatitis B scale. GSK has bepirovirsen. SBP Group may decide whether science can become real-world access.

Read More
Representative image: Advanced lung cancer research and oncology treatment planning are becoming central to the debate over whether Kelun-Biotech’s sacituzumab tirumotecan and pembrolizumab combination can reshape first-line NSCLC care.
Pharma & Biotech

Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market

ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.

Read More
Representative image: A subcutaneous Alzheimer’s treatment injector is shown in a clinical consultation setting as Eisai Co., Ltd. and Biogen Inc. await the FDA’s August 2026 decision on Leqembi Iqlik as a starting dose for early Alzheimer’s disease.
Pharma & Biotech

FDA review extension keeps Eisai and Biogen waiting on Leqembi Iqlik starting-dose strategy

Alzheimer’s drugs need easier delivery. Eisai and Biogen now face an FDA timing test that could shape Leqembi’s access story.

Read More